RESEARCH TRIANGLE PARK, N.C. - Wednesday, July 2nd 2014 [ME NewsWire]
(BUSINESS WIRE)-- Quintiles today announced that it has completed the acquisition of Encore Health Resources (Encore), a leader in the health-information analytics and technology consulting services industry focused on healthcare providers.
“We are extremely pleased to have completed the acquisition of Encore,” said Scott Evangelista, president, Integrated Commercial Services and Solutions at Quintiles. “The addition of Encore greatly enhances our electronic health records expertise – an area that continues to grow in importance as payers, providers and biopharmaceutical customers increase their focus on real-world evidence. We are excited about working together with the Encore team and leveraging the expertise each organization possesses to help our customers improve their probability of success.”
Now known as “Encore, A Quintiles Company,” Encore will operate as part of Quintiles’ Integrated Healthcare Services segment.
About Quintiles
Quintiles (NYSE: Q), a Fortune 500 company, is the world’s largest provider of biopharmaceutical development and commercial outsourcing services. With a network of more than 29,000 employees conducting business in approximately 100 countries, we helped develop or commercialize all of 2013’s top-100 best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes. To learn more about Quintiles, please visit www.quintiles.com.
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect, among other things, Quintiles’ current expectations and anticipated results of operations, all of which are subject to known and unknown risks, uncertainties and other factors that may cause Quintiles’ actual results, performance or achievements, market trends, or industry results to differ materially from those expressed or implied by such forward-looking statements. Therefore, any statements contained herein that are not statements of historical fact may be forward-looking statements and should be evaluated as such. Without limiting the foregoing, the words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “should,” “guidance,” “targets,” “will” and the negative thereof and similar words and expressions are intended to identify forward-looking statements. These statements are subject to risks, uncertainties and assumptions, including our ability to complete, integrate and achieve our intended objectives with respect to the proposed acquisition of Encore and those described under the section entitled "Risk Factors" in Quintiles’ annual report on Form 10-K for the fiscal year ended December 31, 2013, filed with the SEC on February 13, 2014, as such factors may be updated from time to time in Quintiles’ periodic filings with the SEC, which are accessible on the SEC's website at www.sec.gov. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in Quintiles’ filings with the SEC. Unless legally required, Quintiles assumes no obligation to update any such forward-looking statement after the date of this release, whether as a result of new information, future developments or otherwise.
Click here to subscribe to Mobile Alerts for Quintiles.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50897873&lang=en.
Contacts
Quintiles
Phil Bridges, Media Relations (phil.bridges@quintiles.com)
+ 1-919-998-1653
Karl Deonanan, Investor Relations (InvestorRelations@quintiles.com)
+ 1-919-998-2789
No comments:
Post a Comment